European Archives - Page 121 of 1168 - European Medical Journal

The word spotlight on a blue background

Spotlight: February 2025

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to the fore.

Sickle Cell Disease Therapies Remain Underused Despite Proven Benefits

Recent research highlights the significant underuse of disease-modifying therapies for sickle cell disease, despite their established benefits in reducing pain and preventing organ damage.

Genetic Links to High Type 2 Diabetes Risk in Asian Indian Families

New research uncovers explanation for higher rates of Type 2 diabetes in Asian Indian populations.

Oral Immunotherapy with Peanut Butter Boosts Allergy Tolerance in Children

Peanut oral immunotherapy using home-measured peanut butter significantly improves long-term desensitisation in children with high-threshold peanut allergy.

Does Enoxaparin Prevent Thrombosis After Liver Transplant?

These findings challenge existing practices in some institutions that administer prophylactic anticoagulation after liver transplantation.

New Study Shows Haemorrhagic Strokes Double Dementia Risk

Brain haemorrhages double dementia risk, urging regular cognitive screening for affected patients. New research highlights critical clinical implications.

Unveiling the Impact of ANCA Positivity on ILD Outcomes

Study reveals ANCA positivity in 22.4% of patients with ILD, with implications on survival.

Deep Learning Enhances Brain Tumour Segmentation

U-Net neural network achieves 98.56% accuracy in brain tumour segmentation, promising advancements in neurological diagnostics and treatment planning.

UK's NHS must boost medicine spending, ABPI warns

The UK must increase investment in innovative medicines and vaccines if it is to deliver on the NHS 10-Year Plan and drive economic growth.

Angelo Auricchio

Boston Scientific’s Angelo Auricchio on what’s next for heart health

Discover what’s on the horizon for cardiac care and remote monitoring with Angelo Auricchio, Chief Medical Officer, Rhythm Management, Boston Scientific.